Labeling and Promotion Guidances
The FDA’s Center for Biologics Evaluation and Research (CBER) updated its centralized repository of guidance documents specifically governing the labeling and promotion of biological products. This list serves as the primary reference point for current agency thinking on compliant communication for these products.
Manufacturers of biological products, including those under CBER jurisdiction, and personnel responsible for promotional review, labeling development, and regulatory submissions.
Centralized guidance lists are critical for maintaining inspection readiness and ensuring that promotional claims do not exceed the scope of approved labeling. This update likely streamlines the process for industry to identify relevant standards, reducing the risk of receiving Untitled Letters or Warning Letters related to misbranding or off-label promotion. It implies a continued FDA focus on the rigor of promotional materials within the biologics sector.
Regulatory and marketing compliance teams should conduct a gap analysis between current promotional materials and the updated list of CBER-specific labeling and promotion guidance documents. Establish a cadence for monitoring this repository to ensure that future submissions and marketing campaigns align with the latest FDA expectations for biological products.
This page lists Labeling and Promotion Guidance documents.
Open in openFDA / FDA.gov